Kava hepatotoxicity: Regulatory data selection and causality assessment

Digestive and Liver Disease

Volumn 41, Issue 12, 2009, Pages 891-901

  Teschke, R ^a   Wolff, A ^a  

^a Klinikum Hanau   (Germany)

Author keywords

Drug induced liver injury; Herbal hepatotoxicity; Kava hepatotoxicity; Liver disease

Indexed keywords

ALUMINUM HYDROXIDE; ANXIOLYTIC AGENT; ATENOLOL; CISAPRIDE; CRATAEGUS EXTRACT; CYNARA SCOLYMUS EXTRACT; DIAZEPAM; DICLOFENAC; ESTRADIOL; ESTROGEN; FUROSEMIDE; GESTAGEN; GLIMEPIRIDE; HERBACEOUS AGENT; HYDROCHLOROTHIAZIDE; HYPERICUM PERFORATUM EXTRACT; KAVA; KAVA EXTRACT; KAWAIN; LEVOTHYROXINE; LOSARTAN; METFORMIN; OMEPRAZOLE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; RIZATRIPTAN; SALAZOSULFAPYRIDINE; TERFENADINE; UNINDEXED DRUG; VALERIAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DATA ANALYSIS; FEMALE; GERMANY; HUMAN; LIVER DISEASE; LIVER TOXICITY; MALE; PIPER METHYSTICUM; PRIORITY JOURNAL; QUALITY CONTROL; QUANTITATIVE ANALYSIS; RHIZOME;

ADULT; AGED; AGED, 80 AND OVER; CAUSALITY; DRUG-INDUCED LIVER INJURY; FEMALE; GERMANY; HUMANS; KAVA; MALE; MIDDLE AGED; PLANT EXTRACTS;

EID: 70350766713     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2009.04.003     Document Type: Article

References (43)

1. Björnsson E., and Olsson R. Suspected drug-induced liver fatalities reported to the WHO database. Dig Liver Dis 3 (2006) 33-38
2. EMEA. Assessment of case reports connected to herbal medicinal products containing cimicifugae racemosae rhizoma (black cohosh, root). Available at: http://www.emea.europa.eu/pdfs/human/hmpc/26925806en.pdf [Accessed July 18, 2006].
3. Teschke R., and Schwarzenboeck A. Suspected hepatotoxicity by cimicifugae racemosae rhizoma (black cohosh, root): critical analysis and structured causality assessment. Phytomedicine 16 (2009) 72-84
4. BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn. Federal Institute for Drugs and Medicinal Products in Germany); June 14, 2002. http://www.bfarm.de/de/arzneimittel/am_sicher/stufenpl/Besch-kava-Final. pdf.
5. Denham A., McIntyre M., and Whitehouse J. Kava-the unfolding story: report on a work-in-progress. J Altern Complement Med 8 (2002) 237-263
6. Stevinson C., Huntley A., and Ernst E. A systematic review of the safety of kava extract in the treatment of anxiety. Drug Saf 25 (2002) 251-261
7. Teschke R., Gaus W., and Loew D. Kava extracts: safety and risks including rare hepatotoxicity. Phytomedicine 10 (2003) 440-446
8. Schulze J., Raasch W., and Siegers C.P. Toxicity of kava pyrones, drug safety and precautions-a case study. Phytomedicine 10 Suppl. IV (2003) 68-73
9. Loew D., and Franz G. Quality aspects of traditional and industrial kava-extracts. Phytomedicine 10 (2003) 610-612
10. Stickel F., Baumüller H.M., Seitz K., et al. Hepatitis induced by kava (Piper methysticum rhizoma). J Hepatol 39 (2003) 62-67
11. Gow P.J., Connelly N.J., Hill R.L., Crowley P., and Angus P.W. Fatal fulminant hepatic failure induced by a natural therapy containing kava. Med J Aust 178 (2003) 442-443
12. Humberston C.L., Akhtar J., and Krenzelok E.P. Acute hepatitis induced by kava kava. J Toxicol/Clin Toxicol 41 (2003) 109-113
13. Russmann S., Barguil Y., Cabalion P., Kritsanida M., Duhet D., and Lauterburg B.H. Hepatic injury due to traditional aqueous extracts of kava root in New Caledonia. Eur J Gastroenterol Hepatol 15 (2003) 1033-1036
14. Clouatre D.L. Kava kava: examining new reports of toxicity. Toxicol Lett 150 (2004) 85-96
15. Block K.I., Gyllenhaal C., and Mead M.N. Safety and efficacy of herbal sedatives in cancer care. Integr Cancer Ther 3 (2004) 128-148
16. Schmidt M., Morgan M., Bone K., and McMillan J. Kava: a risk-benefit assessment. In: Mills M., and Bone K. (Eds). The essential guide to herbal safety (2005), Elsevier Churchill Livingstone, St. Louis (Missouri) 155-221
17. Schmidt M. Quality criteria for kava. HerbalGram 73 (2007) 45-49
18. Teschke R., Schwarzenboeck A., and Hennermann K.H. Kava hepatotoxicity: a clinical survey and critical analysis of suspected 26 cases. Eur J Gastroenterol Hepatol 20 (2008) 1182-1193
19. Pittler M.H., and Ernst E. Kava extract for treating anxiety (Cochrane Review). Cochrane Library. Issue I (2003), Update Software, Oxford
20. Saß M., Schnabel S., Kröger J., Liebe S., and Schareck W.D. Akutes Leberversagen durch Kava-Kava-eine seltene Indikation zur Lebertransplantation. Z Gastroenterol 39 (2001) 29
21. Brauer R.B., Pfab R., Becker K., Berger H., and Stangl M. Fulminantes Leberversagen nach Einnahme des pflanzlichen Heilmittels Kava-Kava. Z Gastroenterol 39 (2001) P30
22. Strahl S., Ehret V., Dahm H.H., and Maier K.P. Nekrotisierende Hepatitis nach Einnahme pflanzlicher Heilmittel. Dtsch Med Wschr 123 (1998) 1410-1414
23. Kraft M., Spahn T.W., Menzel J., et al. Fulminantes Leberversagen nach Einnahme des pflanzlichen Antidepressivums Kava-Kava. Dtsch Med Wschr 126 (2001) 970-972
24. Schmidt M. Is kava really hepatotoxic? http://www.uni-muenster.de/Chemie/PB/allg_Infos/Kava/page11581.html.
25. Danan G., and Bénichou C. Causality assessment of adverse reactions to drugs. I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 46 (1993) 1323-1330
26. Teschke R., Schwarzenboeck A., and Hennermann K.H. Causality assessment in hepatotoxicity by drugs and dietary supplements. Brit J Clin Pharmacol 66 (2008) 758-766
27. Bénichou C., Danan G., and Flahault A. Causality assessment of adverse reactions to drugs. II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 46 (1993) 1331-1336
28. Lucena M.I., Camargo R., Andrade R.J., Perez-Sanchez C.J., and Sanches de la Cuesta F. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 33 (2001) 123-130
29. Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology 33 (2001) 308-310
30. Lewis J.H. Drug-induced liver disease. Curr Opin Gastroenterol 18 (2002) 307-313
31. Andrade R.J., Camargo R., Lucena M.I., and González-Grande R. Causality assessment in drug-induced hepatotoxicity. Expert Opin Drug Saf 3 (2004) 329-344
32. Andrade R.J., Lucena M.I., Fernández M.C., et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 129 (2005) 512-521
33. MCA (Medicine Control Agency). Line listing February 14, 2002.
34. EMEA (European Medicine Agency). Line listing July 10, 2002.
35. Teschke R., Schwarzenboeck A., and Akinci A. Kava hepatotoxicity: a European view. New Zeal Med Ass 121 (2008) 1283. http://www.nzma.org.nz/journal/121-1283 ISSN 1175 8716. Available at: http://www.nzma.org.nz/journal/121-1283
36. Björnsson E. Drug-induced liver injury: Hy's rule revisited. Clin Pharmacol Ther 79 (2006) 521-528
37. De Valle M.B., AV Klinteberg V., Alem N., Olsson R., and Björnsson E. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharamacol Ther 24 (2006) 1187-1195
38. Andrade R.J., Lucena M.I., Kaplowitz N., et al. Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology 44 (2006) 1581-1588
39. Wai C.T., Tan B.H., Chan C.L., Sutedja D.S., Lee Y.M., Khor C., and Lim S.G. Drug-induced liver injury at an Asian center: a prospective study. Liver Int 27 (2007) 244-254
40. Arundel C., and Lewis J.H. Drug-induced liver disease in 2006. Curr Opin Gastroenterol 23 (2007) 244-254
41. Chang C.Y., and Schiano T.D. Review article: drug hepatotoxicity. Aliment Pharmacol Ther 25 (2007) 1135-1151
42. Bleibel W., Kim S., D'Silva K., and Lemmer E.R. Drug-induced liver injury: review article. Dig Dis Sci 52 (2007) 2463-2471
43. Shapiro M.A., and Lewis J.H. Causality assessment of drug-induced hepatotoxicity: promises and pitfalls. Clin Liver Dis 11 (2007) 477-505